

Ascendiant Capital Markets LLC serves as Placement Agent on \$3,200,000 Private Placement for Hemispherx Biopharma

IRVINE, Calif., September 28, 2018 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a \$3,200,000 private placement for Hemispherx Biopharma, Inc. (NYSE American: HEB) of Ocala, Florida.

Ascendiant served as the sole Placement Agent on the transaction.

Hemispherx intends to use of the proceeds from the transaction for clinical trial activities, working capital, and other general corporate purposes.

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. (NYSE American: HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Hemispherx's manufacturing and operations facility is located in New Brunswick, New Jersey.

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.